References
[1] Lee, T.S., Seong, S.J., Kim, J.W., Ryu, H.S., Song, E.S. and Nam, B.H. (2011) Management of Endometrial Hyperplasia with a Levonorgestrel-Releasing Intrauterine System: Single Arm, Prospective Multicenter Study: Korean Gynecologic Oncology Group Study (KGOG2006). Japanese Journal of Clinical Oncology, 41, 817-819.
http://dx.doi.org/10.1093/jjco/hyr048
[2] Lacey, J.V. and Chia, V.M. (2009) Endometrial Hyperplasia and the Risk of Progression to Carcinoma. Maturitas, 63, 39-44.
http://dx.doi.org/10.1016/j.maturitas.2009.02.005
[3] Varma, R., Soneja, H., Bhatia, K., et al. (2008) The Effectiveness of a Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Treatment of Endometrial Hyperplasia—A Long-Term Follow-Up Study. European Journal of Obstetrics & Gynecology and Reproductive Biology, 139, 169-175.
http://dx.doi.org/10.1016/j.ejogrb.2008.02.022
[4] Wildemeersch, D., Janssens, D., Pylyser, K., et al. (2007) Management of Patients with Non-Atypical and Atypical Endometrial Hyperplasia with a Levonorgestrel-Releasing Intrauterine System: Long-Term Follow-Up. Maturitas, 57, 210-213.
http://dx.doi.org/10.1016/j.maturitas.2006.12.004
[5] Randall, T.C. and Kurman, R.J. (1997) Progestin Treatment of Atypical Hyperplasia and Well-Differentiated Carcinoma of the Endometrium in Women under Age 40. Obstetrics & Gynecology, 90, 434-440.
http://dx.doi.org/10.1016/S0029-7844(97)00297-4
[6] Wildemeersch, D. and Dhont, M. (2003) Management of Patients with Non-Atypical and Atypical Endometrial Hyperplasia with a Levonorgestrel-Releasing Intrauterine System. American Journal of Obstetrics & Gynecology, 188, 1297-1298.
http://dx.doi.org/10.1067/mob.2003.346
[7] Speroff, L. and Darney, P. (2010) A Clinical Guide for Contraception. 5th Edition, Lippincott Williams, Philadelphia.
[8] Bahmondes, L., Petta, C.A., Fernandes, A. and Monterio, I. (2007) Use of the Levonorgestrel-Releasing Intrauterine System in Women with Endometriosis, Pelvic Pain and Dysmenorrhea. Contraception, 75, S134-S139.
http://dx.doi.org/10.1016/j.contraception.2006.12.008
[9] Bergeron C, and Ferenczy, A. (2001) Endometrial Safety of Continuous Combined Hormone Replacement Therapy with 17β-Oestradiol (1 or 2 mg) and Dydrogesterone. Maturitas, 37, 191-199.
http://dx.doi.org/10.1016/S0378-5122(00)00176-6
[10] Trimble, C.L., Method, M., Leitao, M., Lu, K., Ioffe, O., Hampton, M., Higgins, R., Zaino, R., Mutter, G.L., Society of Gynecologic Oncology Clinical Practice Committee (2012) Management of Endometrial Precancers. Obstetrics & Gynecology, 120, 1160-1175.
[11] Lee, S.Y., Kim, M.K., Park, H., Yoon, B.S., Seong, S.J., Kang, J.H., Jun, H.S. and Park, C.T. (2010) The Effectiveness of Levonorgestrel Releasing Intrauterine System in the Treatment of Endometrial Hyperplasia in Korean Women. Journal of Gynecologic Oncology, 21, 102-105.
[12] Clark, T.J., Neelakantan, D. and Gupta, J.K. (2006) The Management of Endometrial Hyperplasia: An Evaluation of Current Practice. European Journal of Obstetrics & Gynecology and Reproductive Biology, 125, 259-264.
http://dx.doi.org/10.1016/j.ejogrb.2005.09.004
[13] Bese, T., Vural, A., Ozturk, M., Dagistanli, F., Demirkiran, F., Tuncdemir, M., et al. (2006) The Effect of Long-Term Use of Progesterone Therapy on Proliferation and Apoptosis in Simple Endometrial Hyperplasia without Atypia. International Journal of Gynecological Cancer, 16, 809-813.
http://dx.doi.org/10.1111/j.1525-1438.2006.00533.x
[14] Marsden, D.E. and Hacker, N.F. (2001) Optimal Management of Endometrial Hyperplasia. Best Practice & Research Clinical Obstetrics & Gynaecology, 15, 393-405.
http://dx.doi.org/10.1053/beog.2000.0184
[15] Vereide, A.B., Arnes, M., Straume, B., Maltau, J.M. and Orbo, A. (2003) Nuclear Morphometric Changes and Therapy Monitoring in Patients with Endometrial Hyperplasia: A Study Comparing Effects of Intrauterine Levonorgestrel and Systemic Medroxyprogesterone. Gynecologic Oncology, 91, 526-533.
http://dx.doi.org/10.1016/j.ygyno.2003.07.002
[16] Gallos, I.D., Shehmar, M., Thangaratinam, S., et al. (2010) Oral Progestogens vs Levonorgestrel-Releasing Intrauterine System for Endometrial Hyperplasia: A Systematic Review and Metaanalysis. American Journal of Obstetrics & Gynecology, 203, 547.e1-10.
[17] Orbo, A., Arnes, M., Hancke, C., Vereide, A.B., Pettersen, I. and Larsen, K. (2008) Treatment Results of Endometrial Hyperplasia after Prospective D-Score Classification: A Follow-Up Study Comparing Effect of LNG-IUD and Oral Progestins versus Observation Only. Gynecologic Oncology, 111, 68-73.
http://dx.doi.org/10.1016/j.ygyno.2008.06.014
[18] Reed, S.D., Voigt, L.F., Newton, K.M., et al. (2009) Progestin Therapy of Complex Endometrial Hyperplasia with and without Atypia. Obstetrics & Gynecology, 113, 655-622.
http://dx.doi.org/10.1097/AOG.0b013e318198a10a
[19] Davis, S.L. and George, M.S. (2006) Estrogens and Progestins. In: Laurence, L.B., John, S.L. and Keith, L.P., Eds., Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11th Edition, McGraw-Hill, New York, 1541-1571, ISBN 0-07-142280-3.
[20] Demirkiran, F., Yavuz, E., Erenel, H., Bese, T., Arvas, M. and Sanioglu, C. (2012) Which Is the Best Technique for Endometrial Sampling? Aspiration (Pipelle) versus Dilatation and Curettage (D & C). Archives of Gynecology and Obstetrics, 286, 1277-1282.
http://dx.doi.org/10.1007/s00404-012-2438-8
[21] Panay, N., Hamoda, H., Arya, R. and Savvas, M. (2013) The 2013 British Menopause Society & Women’s Health Concern Recommendations on Hormone Replacement Therapy. Post Reproductive Health, Published online before print, 23 May 2013.
[22] Leitao Jr., M.M., Han, G., Lee, L.X., Abu-Rustum, N.R., Brown, C.L., Chi, D.S., et al. (2010) Complex Atypical Hyperplasia of the Uterus: Characteristics and Prediction of Underlying Carcinoma Risk. American Journal of Obstetrics & Gynecology, 203, 349.e1-e6.
[23] Guido, R.S., Kanbour-Shakir, A., Rulin, M.C. and Christopherson, W.A. (1995) Pipelle Endometrial Sampling. Sensitivity in the Detection of Endometrial Cancer. The Journal of Reproductive Medicine, 40, 553-555.